Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab prophylaxis safety and tolerability study in hemophilia A with factor VIII inhibitors
MOH_2017-11-29_000588Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoint: Overall safety and tolerability of prophylactic emicizumab. Started Jul 2017; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2017-11-29_000588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-29_000588.